1Ichikawa D, Koike H, Ikoma H,et al.Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer.Anticancer Res,2004, 24(4): 2477-2481.
2Basfian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol,2004, 46(6):698-708.
3Robert MF, Morin S, Beaulieu N,et al.DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.Nat Genet, 2003, 33(1):61-65.
4Etoh T, Kanai Y, Ushijima S. Increased DNA methyltransferase 1(DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol, 2004,164(2):689-699.
5Rhee I, Bachman KE, Park BH, et al.DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature, 2002,416(6880):552-556.
6Hu K, Zhong G, He F. Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer,2005,15(3):537-541.
7Arnett-Mansfield RL, deFazio A, Wain GV, et al.Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.Cancer Res,2001,61(11):4576-4582.
8Miyamoto T, Watanabe J, Hata H,et al.Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. J Steroid Biochem Mol Biol, 2004,92(3):111-118.
9Schiff R, Massarweh S, Shou J, et al. Breast cancer endocrine resistance:how growth factor signaling and estrogen receptor coregulators modulate response.Clin Cancer Res,2003, 9(1 pt 2):447S-454S.
10Leu YW, Yan PS, Fan M,et al.Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.Cancer Res,2004,64(22):8184-8192.
